Large genomic deletions in CACNA1A cause episodic ataxia type 2

Frontiers in Neurology

Volumn SEP, Issue , 2011, Pages

  Wan, Jijun ^a   Mamsa, Hafsa ^a   Johnston, Janine L ^b   Spriggs, Elizabeth L ^b,c   Singer, Harvey S ^d   Zee, David S ^d   Al Bayati, Alhamza R ^a   Baloh, Robert W ^a,e   Jen, Joanna C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Diagnostic Services of Manitoba Inc   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CACNA1A; EA2; Episodic ataxia; Genomic rearrangement; Mutation

Indexed keywords

EID: 84865850387     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2011.00051     Document Type: Article

References (26)

1. Alvina, K., and Khodakhah, K. (2010). The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J. Neurosci. 30, 7258-7268.
2. Cordaux, R., and Batzer, M. A. (2009). The impact of retrotransposons on human genome evolution. Nat. Rev. Genet. 10, 691-703.
3. Cuenca-Leon, E., Banchs, I., Serra, S. A., Latorre, P., Fernandez-Castillo, N., Corominas, R., Valverde, M. A., Volpini, V., Fernandez-Fernandez, J. M., Macaya, A., and Cormand, B. (2009). Late-onset episodic ataxia type 2 associated with a novel loss-of-function mutation in the CACNA1A gene. J. Neurol. Sci. 280, 10-14.
4. Denier, C., Ducros, A., Vahedi, K., Jou-tel, A., Thierry, P., Ritz, A., Castel-novo, G., Deonna, T., Gerard, P., Devoize, J. L., Gayou, A., Perrouty, B., Soisson, T., Autret, A., Warter, J. M., Vighetto, A., Van Bogaert, P., Alamowitch, S., Roullet, E., and Tournier-Lasserve, E. (1999). High prevalence of CACNA1A trunca-tions and broader clinical spectrum in episodic ataxia type 2. Neurology 52, 1816-1821.
5. Graves, T. D., and Hanna, M. G. (2008). Episodic ataxia: SLC1A3 and CACNB4 do not explain the appar-ent genetic heterogeneity. J. Neurol. 255, 1097-1099.
6. Griggs, R. C., Moxley, R. T. III, Lafrance, R. A., and McQuillen, J. (1978). Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 28, 1259-1264.
7. Imbrici, P., Eunson, L. H., Graves, T. D., Bhatia, K. P., Wadia, N. H., Kull-mann, D. M., and Hanna, M. G. (2005). Late-onset episodic ataxia type 2 due to an in-frame inser-tion in CACNA1A. Neurology 65, 944-946.
8. Jen, J., Kim, G. W., and Baloh, R. W. (2004). Clinical spectrum of episodic ataxia type 2. Neurology 62, 17-22.
9. Jen, J. C., Graves, T. D., Hess, E. J., Hanna, M. G., Griggs, R. C., Baloh, R. W., and CINCH Investigators. (2007). Primary episodic ataxias: diagnosis, pathogenesis and treat-ment. Brain 130, 2484-2493.
10. Jeng, C. J., Chen, Y. T., Chen, Y. W., and Tang, C. Y. (2006). Dominant-negative effects of human P/Q-type Ca2+ channel mutations associated with episodic ataxia type 2. Am. J. Physiol. Cell Physiol. 290, C1209- C1220.
11. Jouvenceau, A., Eunson, L. H., Spauschus, A., Ramesh, V., Zuberi, S. M., Kullmann, D. M., and Hanna, M. G. (2001). Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet 358, 801-807.
12. Labrum, R. W., Rajakulendran, S., Graves, T. D., Eunson, L. H., Bevan, R., Sweeney, M. G., Hammans, S. R., Tubridy, N., Britton, T., Carr, L. J., Ostergaard, J. R., Kennedy, C. R., Al-Memar, A., Kullmann, D. M., Schorge, S., Temple, K., Davis, M. B., and Hanna, M. G. (2009). Large scale calcium channel gene rearrangements in episodic ataxia and hemiplegic migraine: implica-tions for diagnostic testing. J. Med. Genet. 46, 786-791.
13. Mantuano, E., Romano, S., Veneziano, L., Gellera, C., Castellotti, B., Caimi, S., Testa, D., Estienne, M., Zorzi, G., Bugiani, M., Rajabally, Y. A., Barcina, M. J., Servidei, S., Panico, A., Frontali, M.,and Mariotti, C. (2010). Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. J. Neurol. Sci. 291, 30-36.
14. Mezghrani, A., Monteil, A., Watschinger, K., Sinnegger-Brauns, M. J., Barrere, C., Bourinet, E., Nargeot, J., Striess-nig, J., and Lory,P. (2008). A destruc-tive interaction mechanism accounts for dominant-negative effects of misfolded mutants of voltage-gated calcium channels. J. Neurosci. 28, 4501-4511.
15. Ophoff, R. A., Terwindt, G. M., Ver-gouwe, M. N., van Eijk, R., Oefner, P. J., Hoffman, S. M., Lamerdin, J. E., Mohrenweiser, H. W., Bulman, D. E., Ferrari, M., Haan, J., Lind-hout, D., van Ommen, G. J., Hofker, M. H., Ferrari, M. D., and Frants, R. R. (1996). Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87, 543-552.
16. Page, K. M., Heblich, F., Davies, A., Butcher, A. J., Leroy, J., Bertaso, F., Pratt, W. S., and Dolphin, A. C. (2004). Dominant-negative cal-cium channel suppression by trun-cated constructs involves a kinase implicated in the unfolded protein response. J. Neurosci. 24, 5400-5409.
17. Page, K. M., Heblich, F., Margas, W., Pratt, W. S., Nieto-Rostro, M., Chag-gar, K., Sandhu, K., Davies, A., and Dolphin, A. C. (2010). N termi-nus is key to the dominant nega-tive suppression of Ca(V)2 calcium channels: implications for episodic ataxia type 2. J. Biol. Chem. 285, 835-844.
18. Riant, F., Lescoat, C., Vahedi, K., Kaphan, E., Toutain, A., Soisson, T., Wiener-Vacher, S. R., and Tournier-Lasserve, E. (2010). Identification of CACNA1A large deletions in four patients with episodic ataxia. Neu-rogenetics 11, 101-106.
19. Riant, F., Mourtada, R., Saugier-Veber, P., and Tournier-Lasserve, E. (2008). Large CACNA1A deletion in a fam-ily with episodic ataxia type 2. Arch. Neurol. 65, 817-820.
20. Schouten, J. P., McElgunn, C. J., Waaijer, R., Zwijnenburg, D., Diepvens, F., and Pals, G. (2002). Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30, e57.
21. Strupp, M., Kalla, R., Claassen, J., Adrion, C., Mansmann, U., Klop-stock, T., Freilinger, T., Neuge-bauer, H., Spiegel, R., Dichgans, M., Lehmann-Horn, F., Jurkat-Rott, K., Brandt, T., Jen, J. C., and Jahn, K. (2011). A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77, 269-275.
22. Strupp, M., Kalla, R., Dichgans, M., Freilinger, T., Glasauer, S., and Brandt, T. (2004). Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62, 1623-1625.
23. Weisz, C. J., Raike, R. S., Soria-Jasso, L. E., and Hess, E. J. (2005). Potassium channel block-ers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J. Neurosci. 25, 4141-4145.
24. Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., Wilde, R. G., Karp, G., Takasugi, J., Chen, G., Jones, S., Ren, H., Moon, Y. C., Corson, D., Tur-poff, A. A., Campbell, J. A., Conn, M. M., Khan, A., Almstead, N. G., Hedrick, J., Mollin, A., Risher, N., Weetall,M.,Yeh,S.,Branstrom,A. A., Colacino, J. M., Babiak, J., Ju, W. D., Hirawat, S., Northcutt, V. J., Miller, L. L., Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, S. W., and Sweeney, H. L. (2007). PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87-91.
25. Williams, A., Jahreiss, L., Sarkar, S., Saiki, S., Menzies, F. M., Ravikumar, B., and Rubinsztein, D. C. (2006). Aggregate-prone proteins are cleared from the cytosol by autophagy: ther-apeutic implications. Curr. Top. Dev. Biol. 76, 89-101.
26. Wilton, S. D., Fall, A. M., Harding, P. L., McClorey, G., Coleman, C., and Fletcher, S. (2007). Antisense oligonucleotide-induced exon skip-ping across the human dystrophin gene transcript. Mol. Ther. 15, 1288-1296.